The estimated Net Worth of Donald H. Mac Adam is at least $202 mil dollars as of 9 July 2021. Mr. Adam owns over 10,000 units of XBiotech Inc stock worth over $64,700 and over the last 7 years he sold XBIT stock worth over $0. In addition, he makes $137,000 as Independent Director at XBiotech Inc.
Donald has made over 1 trades of the XBiotech Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of XBIT stock worth $44,000 on 9 July 2021.
The largest trade he's ever made was exercising 10,000 units of XBiotech Inc stock on 9 July 2021 worth over $44,000. On average, Donald trades about 1,111 units every 0 days since 2018. As of 9 July 2021 he still owns at least 10,000 units of XBiotech Inc stock.
You can see the complete history of Mr. Adam stock trades at the bottom of the page.
Donald H. MacAdam serves as Independent Director of the Company. r. MacAdam is a technology executive with extensive public and private company experience. He is a currently a director of Hammond Power Solutions (TSE:HPS.A) and was formerly CEO of MBVax Bioscience, director of CTL Immunotherapies, CEO of Tm Bioscience (TSE), president of CRS Robotics (TSE), and CEO of L.A. Varah Ltd. (TSE). He is the inventor under several patents and the author of three books: Startup to IPO, Spontaneous Regression Cancer and the Immune System, and The Resonance Model.
As the Independent Director of XBiotech Inc, the total compensation of Donald MacAdam at XBiotech Inc is $137,000. There are 6 executives at XBiotech Inc getting paid more, with John Simard having the highest compensation of $10,810,400.
Donald's mailing address filed with the SEC is 56 Kelly Dr, Port Dover, ON N0A 1N5, Canada.
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes, eW Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: